Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Prothena Corporation plcNASDAQ: PRTA

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital growth accelerates

Q1 FY2026 change in working capital of $6.48M (cash outflow) rose 93.1% year over year, ahead of the -87.4% change in trailing-twelve-month change in working capital. Sequentially, it fell 34.2% from the prior quarter. Over 3 fiscal years it compounded at -39.5% a year.

Context

  • Change in working capital amounted to 43.1% of revenue in FY2025, down 7.2 pp from a year earlier.
  • Change in working capital grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +93.1% holds above the trailing-twelve-month pace of -87.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.48M-34.2% QoQ
Last fiscal yearDec 2025
-$4.17M-93.9% YoY
LTMMar 2026
-$7.3M-87.4% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+93.1%——
1 year-93.9%——
3-year CAGR-39.5%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(4.17M) USD
Year-over-year change
+93.9%

Change in Working Capital vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -87.4% is the 3rd highest of 10, against a peer median of -122.0%.
  • Change in working capital amounts to 12.6% of revenue for PRTA, versus a peer median of 130.0%.
PRTA Competitors
Change in Working Capital for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$65.5M USD+107.6%+5.9%0.7%
DNLIDenali Therapeutics Inc.LTM Jun 2026$24.36M USD-157.6%—675.8%
PRTAProthena Corporation plcLTM Mar 2026$7.3M USD-87.4%-39.5%12.6%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$4.73M USD-383.2%——
ACIUAC Immune S.A.LTM Dec 2025CHF 4.65M CHF-104.3%-8.4%130.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$3.5M USD-141.8%——
ANNXAnnexon, Inc.LTM Mar 2026$3.08M USD-122.0%+4.2%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$2.8M USD+129.3%+54.2%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$677K USD-103.7%-60.2%—
PMNProMIS Neurosciences, Inc.LTM Jun 2026$601.5K USD-126.4%+14.0%—
Peer median (excluding PRTA) —-122.0%+5.1%130.0%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Depreciation & Amortization1.12M744K928K893K895K
Deferred Income Tax4.57M(11.13M)(15.69M)(9.35M)43.24M
Stock-Based Compensation24.66M31.32M40.91M45.96M37.64M
Change in Working Capital(10.4M)(18.8M)(20.53M)(67.94M)(4.17M)
Accounts Receivables15K0(5.16M)5.16M0
Inventory00(8.9M)00
Accounts Payables(492K)11.87M22.86M(18.3M)(15.78M)
Other Working Capital(9.93M)(30.67M)(29.33M)(54.8M)11.6M
Other Non-Cash Items5.69M6M7.5M2.69M2.91M
Operating Cash Flow92.61M(108.82M)(133.91M)(150.05M)(163.58M)
Capital Expenditures(575K)(464K)(2.81M)(298K)(138K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0037K00
Investing Cash Flow(575K)(464K)(2.77M)(298K)(138K)
Debt Repayment00000
Common Stock Issued174.79M223.62M23.58M0(139K)
Common Stock Repurchased000(353K)0
Dividends Paid00000
Other Financing Activities15.54M17.84M21.52M1.91M0
Financing Cash Flow190.33M241.46M45.1M1.55M(139K)
Effect of Forex Changes00000
Net Change in Cash282.36M132.17M(91.58M)(148.79M)(163.86M)
Free Cash Flow92.03M(109.29M)(136.72M)(150.35M)(163.72M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.